Increased Nuclear Transporter KPNA2 Contributes to Tumor Immune Evasion by Enhancing PD-L1 Expression in PDAC

Kaixia Zhou, Shan Huang, Li-Peng Hu, Xueli Zhang, Weiting Qin, Yanli Zhang, Linli Yao, Yanqiu Yu, Yao-Qi Zhou, Lei Zhu, Jianguang Ji, Zhigang ZhangJournal of Immunology Research 2021 · DOI

TL;DR

This study reveals that increased expression of the nuclear transporter KPNA2 in pancreatic ductal adenocarcinoma (PDAC) promotes tumor immune evasion by upregulating PD-L1. This mechanism, mediated by KPNA2's role in STAT3 nuclear translocation, suggests KPNA2 could be a valuable diagnostic biomarker and therapeutic target for PDAC.

What Problem Does This Paper Address?

Pancreatic ductal adenocarcinoma (PDAC) is notoriously aggressive, characterized by high resistance to treatment and a dismal 5-year survival rate. A major hurdle in developing effective therapies is "tumor immune evasion," where cancer cells actively suppress the immune system's ability to attack them. While the nuclear transporter Karyopherin alpha 2 (KPNA2) is known to be elevated in various cancers and linked to carcinogenesis, its specific role in PDAC, particularly in immune evasion, remained unclear. This paper aims to elucidate KPNA2's function in PDAC and its contribution to tumor progression and immune evasion.

Methods

The researchers employed a multi-pronged approach:

  • Data Mining: They analyzed publicly available gene expression datasets (GEO and TCGA) to assess KPNA2 expression levels in PDAC tumors versus adjacent normal tissues and to correlate KPNA2 expression with patient survival.
  • In Vitro Studies:
    • Cell Culture: Human PDAC cell lines (MIA PaCa-2, PANC-1) and a mouse PDAC cell line (KPC1199-luc) were used.
  • Gene Silencing: Lentivirus-mediated shRNA was used to specifically knock down KPNA2 expression in these cell lines.
  • Proliferation and Migration Assays: CCK-8 assays were used to measure cell viability, and wound healing assays assessed cell migration.
  • Immunofluorescence: This technique was used to visualize the localization of KPNA2 and STAT3 within cells, specifically their translocation into the nucleus.
  • Western Blotting and qPCR: These molecular biology techniques were used to quantify protein and mRNA levels of KPNA2, PD-L1, and phosphorylated STAT3 (p-STAT3).
  • Flow Cytometry: Used to measure PD-L1 expression on the surface of cancer cells.
  • In Vivo Studies:
    • Animal Models: Orthotopic PDAC models were established in mice by injecting PDAC cells.
  • Bioluminescence Imaging: Used to monitor tumor growth in real-time.
  • Histological Analysis (IHC and H&E): Immunohistochemistry (IHC) was used to visualize KPNA2, CD8 (a marker for cytotoxic T cells), and Granzyme B (an enzyme released by cytotoxic T cells) in tumor tissues. Hematoxylin and eosin (H&E) staining provided general tissue morphology.
  • Pathway Analysis: Gene Set Enrichment Analysis (GSEA) was performed to identify biological pathways affected by KPNA2 expression.

Datasets

  • GEO Datasets: GSE15471, GSE16515, GSE62452, GSE28735, and GSE71729 were used for analyzing KPNA2 expression patterns and prognostic value.
  • TCGA Dataset: Used for analyzing KPNA2 expression and its correlation with the IL-6-JAK-STAT3 signaling pathway.
  • KPC Mouse Model: Used for in vivo validation of KPNA2 expression patterns.

Key Insights and Ideas

  • KPNA2 as a Prognostic Indicator: The study strongly suggests that elevated KPNA2 levels in PDAC are not just a correlation but are significantly associated with poorer patient survival. This makes KPNA2 a potential biomarker for predicting disease outcome.
  • In Vitro vs. In Vivo Discrepancy: A key finding is that while KPNA2 knockdown didn't significantly affect PDAC cell viability or migration in vitro, it dramatically reduced tumor growth in vivo. This points towards a critical role for KPNA2 in the tumor's interaction with its environment, particularly the immune system, rather than solely intrinsic cell proliferation.
  • KPNA2 Orchestrates Immune Evasion via PD-L1: The research uncovers that KPNA2 directly influences the expression of PD-L1, a crucial immune checkpoint ligand. By increasing PD-L1, KPNA2 helps cancer cells evade immune detection and destruction.
  • STAT3 as the Molecular Bridge: The study elucidates the mechanism: KPNA2 facilitates the nuclear translocation of STAT3, a transcription factor. STAT3, in turn, directly promotes the expression of PD-L1. This establishes a clear molecular pathway from KPNA2 to immune evasion.
  • KPNA2's Nuclear Role: The findings highlight KPNA2's function as a nuclear transporter, emphasizing how manipulating these fundamental cellular processes can have profound effects on complex biological behaviors like cancer progression and immune interaction.

Key Results

  • KPNA2 expression was significantly upregulated in PDAC tissues compared to adjacent non-tumor tissues across multiple datasets.
  • High KPNA2 expression was correlated with poor overall survival in PDAC patients (log-rank p = 0.0322 in TCGA, p = 0.0166 in GSE71729).
  • Knockdown of KPNA2 in PDAC cell lines (MIA PaCa-2, PANC-1) did not affect cell viability or migration in vitro.
  • In vivo, KPNA2 knockdown significantly reduced tumor burden in orthotopic PDAC mouse models.
  • Silencing KPNA2 led to a significant reduction in PD-L1 expression on PDAC cells, both in vitro and in vivo.
  • KPNA2 knockdown impaired the nuclear translocation of STAT3, and consequently reduced p-STAT3 levels.
  • Inhibition of STAT3 with stattic also reduced PD-L1 expression, confirming STAT3's role.
  • IHC analysis showed reduced CD8+ T cell infiltration and Granzyme B expression in tumors with KPNA2 knockdown, suggesting impaired anti-tumor immunity.

Limitations and Future Work

  • In Vitro vs. In Vivo Discrepancy: While the study provides a compelling explanation for the in vitro vs. in vivo difference (immune evasion), further detailed mechanistic studies could explore other potential contributing factors.
  • KPNA7 vs. KPNA2: The paper briefly mentions KPNA7, a close relative of KPNA2, and its role in promoting malignant properties in vitro. Future work could explore potential functional redundancy or distinct roles between KPNA2 and KPNA7 in PDAC.
  • Therapeutic Translation: While KPNA2 is proposed as a diagnostic biomarker, further research is needed to develop targeted therapies that specifically inhibit KPNA2 or its downstream pathways for clinical application in PDAC.
  • Broader Immune Context: While PD-L1 and CD8/Granzyme B are explored, a more comprehensive analysis of other immune cell populations and cytokines within the tumor microenvironment could provide a richer understanding of KPNA2's impact on immune evasion.

Summary updated

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest malignancies and is known for its high resistance and low response to treatment. Tumor immune evasion is a major stumbling block in designing effective anticancer therapeutic strategies. Karyopherin alpha 2 (KPNA2), a member of the nuclear transporter family, is elevated in multiple human cancers and accelerates carcinogenesis. However, the specific role of KPNA2 in PDAC remains unclear. In this study, we found that expression of KPNA2 was significantly upregulated in PDAC compared to adjacent nontumor tissue and its high expression was correlated with poor survival outcome by analyzing the GEO datasets. Similar KPNA2 expression pattern was also found in both human patient samples and KPC mouse models through IHC staining. Although KPNA2 knockdown failed to impair the vitality and migration ability of PDAC cells <i>in vitro</i>, the <i>in vivo</i> tumor growth was significantly impeded and the expression of immune checkpoint ligand PD-L1 was reduced by silencing KPNA2. Furthermore, we uncovered that KPNA2 modulated the expression of PD-L1 by mediating nuclear translocation of STAT3. Collectively, our data suggested that KPNA2 has the potential to serve as a promising biomarker for diagnosis in PDAC.
BibTeX
@article{zhou2021increased,
  author = {Kaixia Zhou and Shan Huang and Li-Peng Hu and Xueli Zhang and Weiting Qin and Yanli Zhang and Linli Yao and Yanqiu Yu and Yao-Qi Zhou and Lei Zhu and Jianguang Ji and Zhigang Zhang},
  title = {{Increased Nuclear Transporter KPNA2 Contributes to Tumor Immune Evasion by Enhancing PD-L1 Expression in PDAC}},
  journal = {Journal of Immunology Research},
  year = {2021},
  doi = {10.1155/2021/6694392},
}
Figure